The remnants of residual risk

Journal of the American College of Cardiology

Volumn 65, Issue 21, 2015, Pages 2276-2278

  Joshi, Parag H ^a   Martin, Seth S ^a   Blumenthal, Roger S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

atherosclerosis; LDL cholesterol; remnant lipoproteins; risk factors; triglycerides

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DIET RESTRICTION; HIGH RISK POPULATION; HUMAN; LIFESTYLE MODIFICATION; LOW RISK POPULATION; NOTE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK REDUCTION; WEIGHT REDUCTION; BLOOD; FEMALE; MALE;

ACUTE CORONARY SYNDROME; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; TRIGLYCERIDES;

EID: 84930035324     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.03.543     Document Type: Editorial

References (19)

1. S. Mora, N.K. Wenger, and D.A. Demicco Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study Circulation 125 2012 1979 1987
2. M. Miller, N.J. Stone, C. Ballantyne American Heart Association Clinical Lipidology Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism Council on Arteriosclerosis, Thrombosis and Vascular Biology Council on Cardiovascular Nursing Council on the Kidney in Cardiovascular Disease Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association Circulation 123 2011 2292 2333
3. G.G. Schwartz, M. Abt, and W. Bao Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins J Am Coll Cardiol 65 2015 2267 2275
4. G.G. Schwartz, A.G. Olsson, M.D. Ezekowitz for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial JAMA 285 2001 1711 1718
5. G.G. Schwartz, A.G. Olsson, M. Abt for the dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
6. A.B. Jorgensen, R. Frikke-Schmidt, and A.S. West Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction Eur Heart J 34 2013 1826 1833
7. A. Varbo, M. Benn, and A. Tybjaerg-Hansen Remnant cholesterol as a causal risk factor for ischemic heart disease J Am Coll Cardiol 61 2013 427 436
8. A.B. Jorgensen, R. Frikke-Schmidt, and B.G. Nordestgaard Loss-of-function mutations in APOC3 and risk of ischemic vascular disease N Engl J Med 371 2014 32 41
9. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute Loss-of-function mutations in APOC3, triglycerides, and coronary disease N Engl J Med 371 2014 22 31
10. M. Miller, C.P. Cannon, S.A. Murphy for the PROVE IT-TIMI 22 Investigators Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial J Am Coll Cardiol 51 2008 724 730
11. P. Kohli, S.P. Whelton, and S. Hsu Clinician's guide to the updated ABCs of cardiovascular disease prevention J Am Heart Assoc 3 2014 e001098
12. Accord Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
13. AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
14. J.R. Guyton, A.E. Slee, and T. Anderson Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) J Am Coll Cardiol 62 2013 1580 1584
15. M. Yokoyama, H. Origasa, M. Matsuzaki for the Japan EPA Lipid Intervention Study (JELIS) Investigators Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis Lancet 369 2007 1090 1098
16. E.C. Rizos, E.E. Ntzani, and E. Bika Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis JAMA 308 2012 1024 1033
17. Amarin Pharma Inc. A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin (REDUCE-IT). 2014. Available at: https://clinicaltrials.gov/ct2/show/NCT01492361. Accessed March 22, 2015.
18. AstraZeneca. Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH). 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT02104817. Accessed March 22, 2015.
19. M.J. Graham, R.G. Lee, and T.A. Bell 3rd Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans Circ Res 112 2013 1479 1490